A Randomized Phase 2 Study of Human Anti-PDGFR-alpha Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2014
At a glance
- Drugs Olaratumab (Primary) ; Mitoxantrone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly; ImClone Systems
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 17 Apr 2013 Planned number of patients changed from 120 to 123 as reported by German Clinical Trials Register.